Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pharmather Hldgs Ltd
(OP:
PHRRF
)
0.0700
-0.0022 (-3.05%)
Streaming Delayed Price
Updated: 2:09 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pharmather Hldgs Ltd
< Previous
1
2
3
4
Next >
PharmaTher Announces Update on FDA New Drug Application for Ketamine
September 04, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 10, 2024
The FDA Assigned Goal Date is October 29, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 18, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 12, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
↗
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
PharmaTher Provides Update for Expected FDA Approval of Ketamine
January 10, 2024
Assigned FDA approval goal date of April 29, 2024, is still on track
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
↗
October 02, 2023
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...
Via
Benzinga
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
↗
September 27, 2023
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.
Via
Benzinga
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
September 27, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
↗
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
↗
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
↗
September 06, 2023
Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t
Via
Benzinga
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
September 06, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
↗
July 24, 2023
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...
Via
Benzinga
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
↗
July 18, 2023
PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.
Via
Benzinga
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
July 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
↗
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
↗
June 28, 2023
Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.
Via
Benzinga
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
↗
June 27, 2023
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic...
Via
Benzinga
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
June 27, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
↗
June 20, 2023
Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary...
Via
Benzinga
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
June 20, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
PharmaTher Holdings Provides Corporate Update
June 12, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
